Travatrelvir - Traws Pharma
Alternative Names: 83-0060; MPro; Ratutrelvir; Ratutrelvir - Traws Pharma; TRX 01Latest Information Update: 27 Feb 2026
At a glance
- Originator Trawsfynydd Therapeutics
- Developer Traws Pharma
- Class Antivirals; Small molecules
- Mechanism of Action Coronavirus 3C-like proteinase inhibitors
-
Orphan Drug Status
No
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- Phase II COVID 2019 infections
Most Recent Events
- 19 Feb 2026 Efficacy and adverse event data from a phase II trial in COVID-2019 infections released by Traws Pharma
- 19 Feb 2026 Traws Pharma completes a phase II for COVID-2019 infections in Australia, South Korea, Taiwan and Uzbekistan (PO) (NCT07157007)
- 26 Jan 2026 Traws Pharma completes enrolment in its phase II for COVID-2019 infections in Australia, South Korea, Taiwan and Uzbekistan (PO) (NCT07157007)